Please use this identifier to cite or link to this item:
|Title:||Drug Prices - How Much is too Much?|
|Authors:||Nair, Manu S|
|Keywords:||Drug price;Drug cost;Affordable drug price;Compulsory license;Drug development;Intellectual property monetization;Biopharma investment;How much is too much;Greed|
|Abstract:||Rising healthcare costs have made drug pricing a controversial issue worldwide. ‘How much is too much’ is a question that is consistently asked in this context. While there are several factors contributing to rising drug prices, strong intellectual property (IP) laws and the efforts of private sector to monetize such IP are widely blamed for such outcome. Hence, it is important to have an open discussion on this topic to analyse whether such blame is justified. An effort is made herein to perform a concise business review to shed light on the market realities around drug pricing and the important role that a strong IP landscape plays in driving innovation, quality and sustained growth of healthcare economy.|
|ISSN:||0975-1076 (Online); 0971-7544 (Print)|
|Appears in Collections:||JIPR Vol.17(5) [September 2012]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.